ArchiMed acquires Esperion

ARCHIMED has entered into an agreement to acquire Esperion Therapeutics, Inc., a biopharmaceutical company, for a total equity value that could reach $1.1 billion. The acquisition price includes an initial payout of $3.16 per share in cash and contingent milestone payments contingent upon future performance. This acquisition highlights ARCHIMED’s strategic focus on enhancing its footprint in the healthcare sector, specifically targeting the cardiovascular and primary care markets.

In detail, ARCHIMED will pay Esperion shareholders $3.16 per share in cash, which marks a 58% premium over Esperion’s closing share price as of April 30, 2026. Additionally, shareholders may receive up to $100 million in milestone payments linked to the future sales of Esperion's core products, including drugs based on bempedoic acid and bumetanide. These contingent milestone payments are to be disbursed between 2027 and 2030 based on specific sales targets: an aggregate of up to $40 million is tied to U.S. net sales of bempedoic acid-based products, while up to $60 million hinges on bumetanide product sales.

Esperion, established in 2008, has carved out a niche in developing treatments for cardiometabolic conditions and other rare diseases. Sheldon Koenig, Esperion’s CEO, emphasized that this deal offers immediate financial benefits to its shareholders and potential future gains through milestone payments. He noted that ARCHIMED’s backing would enable Esperion to advance its Vision 2040 strategy aimed at reducing the global burden of cardiometabolic diseases.

The acquisition positions ARCHIMED to capitalize on Esperion's existing product portfolio, further anchoring the investment firm in the biopharmaceutical sector's burgeoning markets. Given the rising demand for innovative treatments addressing cardiovascular diseases, a major health concern worldwide, ARCHIMED plans to leverage Esperion’s expertise to accelerate market penetration and product development.

Esperion's Board has unanimously endorsed the transaction, anticipating closure by the third quarter of 2026. The completion is contingent upon standard approvals and shareholder consent. As ARCHIMED and Esperion proceed, the deal will likely be scrutinized for its potential impact on market dynamics and the strategic alignment with broader industry trends in healthcare innovation and capital allocation.